190 related articles for article (PubMed ID: 21072286)
1. Current status of maintenance therapy for advanced ovarian cancer.
Hope JM; Blank SV
Int J Womens Health; 2010 Aug; 1():173-80. PubMed ID: 21072286
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
3. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
4. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
5. A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study.
Kiselev VI; Ashrafyan LA; Muyzhnek EL; Gerfanova EV; Antonova IB; Aleshikova OI; Sarkar FH
BMC Cancer; 2018 Sep; 18(1):904. PubMed ID: 30236079
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
7. Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy.
Nagano H; Tachibana Y; Kawakami M; Ueno M; Morita Y; Muraoka M; Takagi K
Case Rep Oncol; 2016; 9(1):195-204. PubMed ID: 27099605
[TBL] [Abstract][Full Text] [Related]
8. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
9. Rationale for maintenance or consolidation therapy in ovarian cancer.
Markman M
Clin Adv Hematol Oncol; 2003 Mar; 1(3):176-8. PubMed ID: 16224399
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis inhibitors for the treatment of ovarian cancer.
Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
[TBL] [Abstract][Full Text] [Related]
12. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.
Rochet N; Kieser M; Sterzing F; Krause S; Lindel K; Harms W; Eichbaum MH; Schneeweiss A; Sohn C; Debus J
BMC Cancer; 2011 Jan; 11():41. PubMed ID: 21276234
[TBL] [Abstract][Full Text] [Related]
13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
Lin Q; Liu W; Xu S; Shang H; Li J; Guo Y; Tong J
BJOG; 2021 Feb; 128(3):485-493. PubMed ID: 32654312
[TBL] [Abstract][Full Text] [Related]
15. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.
Muggia FM
Semin Oncol; 2006 Dec; 33(6 Suppl 12):S18-24. PubMed ID: 17223446
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer.
Auranen A; Grénman S
Int J Gynecol Cancer; 2008; 18 Suppl 1():44-6. PubMed ID: 18336400
[TBL] [Abstract][Full Text] [Related]
19. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Ray-Coquard I; Mirza MR; Pignata S; Walther A; Romero I; du Bois A
Cancer Treat Rev; 2020 Nov; 90():102107. PubMed ID: 33099187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]